Shares of the company are trading at $2.43 which is marginally under the 50 day moving average which is $2.67 and which is just over the 200 day moving average of $2.42. The 50 day moving average moved down $-0.24 whereas the 200 day average was up by +0.25%. Trading was light with 43K shares changing hands on Tuesday. Trading volume was down 96.96% under the stocks average daily volume.
Short traders are more bullish on shares of the company of late as evidenced by the motion in short interest. The company recorded a fall in short interest of -19.60% as of September 29, 2017 from the last reporting period. Short interest decreased from 16,176,982 to 13,005,531 over that timeframe. The days to cover increased to 13.0 and the percentage of shorted shares was 0.11% on September 29.
Here are a few substantial investment firms who have updated their positions. Ubs Group Ag downsized its stake by selling 10,315 shares a decrease of 79.5%. Ubs Group Ag currently owns 2,660 shares with a value of $7,000. The value of the position overall is down by 68.2%. Sheets Smith Wealth Management augmented its investment by buying 39,560 shares an increase of 31.6% from 06/30/2017 to 09/30/2017. Sheets Smith Wealth Management now controls 164,888 shares worth $453,000. The total value of its holdings increased 33.2%.
Mesirow Financial Investment Management International Equity bolstered its position by buying 3,016 shares an increase of 2.6% in the quarter. Mesirow Financial Investment Management International Equity now holds 119,169 shares valued at $328,000. The total value of its holdings increased 4.1%. As of quarter end Diamond Hill Capital Management Inc had disposed of a total of 468,943 shares trimming its position 11.0%. The value of the investment in BIOS decreased from $11,593,000 to $10,453,000 a change of $1,140,000 since the last quarter.
On August 10 the stock rating was upgraded to “Buy” from “Neutral” in a statement from SunTrust Robinson Humphrey.
As of the last earnings report the EPS was $-0.69 and is expected to be $-0.55 for the current year with 127,475,000 shares now outstanding. Next quarter’s EPS is estimated at $-0.03 and the next full year EPS is projected to be $-0.17.
BioScrip, Inc., launched on March 22, 1996, is involved in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications..